5:02 PM
 | 
Sep 25, 2007
 |  BC Extra  |  Top Story

FDA wants more Retaane data

Alcon (ACL) received an approvable letter from FDA for an NDA for Retaane anecortave to treat wet age-related macular degeneration (AMD). FDA told the company that approval would require an additional clinical trial; however, the company said it has no...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >